Cartesian Therapeutics (RNAC) Common Equity (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Common Equity data on file, last reported at -$148.1 million in Q1 2026.

• Common Equity for Q1 2026 came in at -$148.1 million, down 579.78% year-over-year; the trailing twelve-month figure through Mar 2026 was -$148.1 million (down 579.78% YoY), and the FY2025 annual result was -$126.2 million, down 1755.92% from the prior year.
• Common Equity declined to -$148.1 million in Q1 2026 per RNAC's latest filing, from -$126.2 million in the prior quarter.
• Over five years, Common Equity peaked at $93.8 million in Q4 2022 and troughed at -$440.2 million in Q4 2023.
• A 5-year average of -$27.9 million and a median of -$2.5 million in 2025 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2025: Common Equity soared 2222.36% in 2022, then slumped 4866.49% in 2025.
• A 5-year view of Common Equity shows it stood at $93.8 million in 2022, then slumped by 569.14% to -$440.2 million in 2023, then jumped by 98.45% to -$6.8 million in 2024, then sank by 1755.92% to -$126.2 million in 2025, then declined by 17.33% to -$148.1 million in 2026.
• Business Quant data shows RNAC's Common Equity at -$148.1 million in Q1 2026, -$126.2 million in Q4 2025, and -$35.8 million in Q3 2025.